Navigation Links
Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology
Date:3/8/2011

HOUSTON, March 8, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced the publication of studies comparing AP1903-activated iMyD88/CD40-transduced dendritic cells (DCs) to conventionally matured DCs, in the April 2011 issue of The Journal of Clinical Investigation (JCI).  The studies, conducted by researchers at Baylor College of Medicine, explored the feasibility of a second generation DeCIDe™ vector that combines an inducible toll like receptor (TLR) adapter molecule, iMyD88, with the first generation's inducible CD40 receptor, iCD40.

In the JCI publication, published online on March 7, Narayanan et al reported that chemically induced dimerization (CID) of iMyD88 can replace exogenous, pro-inflammatory adjuvants, providing the danger signal necessary for full DC activation.  Moreover, the manuscript shows for the first time that CD40 and MyD88 signaling domains may be fused into the same iMyD88/CD40 chimeric CID protein, which when activated by AP1903 leads to:  

  • Synergistic activation of downstream signaling molecules in primary DCs.
  • Elaboration of high, therapeutic levels of the T helper 1 (Th1) polarizing cytokine, IL-12, leading to the efficient expansion of CD8+ cytotoxic T lymphocytes (CTLs) in vivo.
  • Full activation of DCs within lymph nodes, the physiologically appropriate site for activation.
  • Elimination of a variety of pre-established tumors in mice, including aggressive B16 melanoma.

"By incorporating TLR signaling into the DeCIDe™ vector, we avoid the need for exogenous TLR adjuvants, while also achieving more potent antitumor activity," stated corresponding author Dr. David Spencer, Vice Chairman of the Department of Pathology and Immunology at Baylor College of Medicine, and Bellicum's Chief Scientific Officer.

Bellicum is working to incorporate this second generation technology into future DeCIDe™ vaccines based on DNA encoding both the iMyD88/CD40 protein and an antigen. In conjunction with a delivery mechanism targeting this DNA to DCs in vivo, such a vaccine could be supplied off the shelf.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft vs. host disease (GvHD). For more information, visit http://www.bellicum.com.


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
2. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
3. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
4. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
6. Tips from the journals of the American Society for Microbiology
7. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
8. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
9. Publication on Tregitopes in Blood Journal of October 2008
10. The Lancets New Online Medical Journal Helps Clinicians and Medical Researchers Find Practice-Changing Evidence Quickly and Easily
11. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... coverage option for U.S. consumers who want to have ... DarioHealth has signed strategic alliance agreements with partners across ... coverage benefits, and if approved, will supply and bill ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
Breaking Biology Technology:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):